<p><strong><em>本研究在同行评审期刊上的发表预计将解锁 500 万美元的合同里程碑付款</em></strong></p>
<p>, /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX)（&#34;Volition&#34;），一家跨国表观遗传学公司，宣布提交一篇临床手稿进行同行评审，报告其 Nu.Q® Vet Feline 原型检测在检测猫淋巴瘤（该物种中最常见的癌症）方面的高准确性。该检测在 97% 的特异性下检测到了 86% 的猫淋巴瘤。这一突破标志着我们预计将开发出全球首个简单、经济的基于血液的猫癌症液体活检测试，这在兽医学中是一个重要的未满足需求。</p>
<p><strong>安娜丽莎·卡纳莱博士，</strong> Volition 的首席作者评论道：</p>
<p>&#34;猫肿瘤学缺乏肿瘤生物标志物，因此猫的癌症早期诊断一直非常困难。</p>
<p>&#34;基于我们之前对犬淋巴瘤的研究，本研究旨在强调循环核小体作为生物标志物的实用性，以区分健康与中大型细胞淋巴瘤的猫。</p>
<p>&#34;中大型细胞淋巴瘤的猫的核小体水平显著高于健康对照，表明 H3.1-核小体作为筛查猫中大型细胞淋巴瘤的新有用生物标志物的潜在作用。&#34;</p>
<p><strong>盖尔·福特尔，</strong> Volition 首席商业官评论道：</p>
<p>&#34;这代表了 Volition 的巨大商业机会：</p>
<ul>
<li>本研究在同行评审期刊上的发表预计将解锁 500 万美元的合同里程碑付款；并且</li>
<li>我们计划在这个庞大且快速增长的市场中产生持续的收入，我们的技术满足了未满足的需求。</li>
</ul>
<p>&#34;我们的使命是使癌症筛查成为每只宠物年度健康检查的常规部分，在成功国际推广我们的犬癌症检测后，我们现在已经证明我们的技术对猫也有效。</p>
<p>&#34;我们期待完成产品开发，并通过我们的分销网络（包括参考实验室和即时检测平台）使 Nu.Q® Vet Feline 测试可用。</p>
<p>&#34;Nu.Q® Vet Canine 测试已经在 20 多个国家可用，我们相信增加一个猫的等效测试可能会使我们在伴侣动物领域的总可寻址市场翻倍。&#34;</p>
<p>Nu.Q® Vet Feline 测试切入了一个重要的、快速增长的市场：</p>
<ul>
<li><strong>庞大的人口：</strong> 美国仅有约 <strong>7380 万只宠物猫</strong>。</li>
<li><strong>高风险：</strong> 估计约 <strong>五分之一的猫</strong> 在其一生中会患上癌症。猫淋巴瘤是该物种中最常见的癌症，是 Nu.Q®检测的主要目标。</li>
<li><strong>“老年” 群体：</strong> 超过 <strong>25% 的美国猫</strong> 被认为是老年猫（年龄 8 岁以上），这为美国超过 1800 万只宠物提供了每年定期筛查的机会。</li>
<li><strong>市场增长：</strong> 北美兽医肿瘤学市场预计到 2025 年将达到 <strong>17.7 亿美元</strong>，其中猫的细分市场预计将以比犬类细分市场更快的复合年增长率增长，原因是主人意识的提高和对猫特定治疗的关注增加。&#34;</li>
</ul>
<p>该论文将在接下来的几天内在预印本服务上发布。</p>
<ol>
<li>数据存档</li>
<li>Vail D, Thamm D, Liptak J, eds. Withrow and MacEwen's Small Animal Clinical Oncology. 第 6 版. Elsevier Health Sciences; 2019。</li>
<li>H. M. Wilson‑Robles 等，BMC Vet Res, 2022, https://doi.org/10.1186/s12917-022-03429-8</li>
<li>C. Dolan 等，BMC Vet Res, 2021 https://doi.org/10.1186/s12917-021-02991-x</li>
<li>H. M. Wilson‑Robles 等，BMC Vet Res, 2021, https://doi.org/10.1186/s12917-021-02934-6</li>
<li><em>AVMA 宠物拥有源书</em> <em>(2025)</em> 6 <em>APPA 全国宠物主人调查 (2025)</em></li>
<li>猫会得癌症吗？了解猫淋巴瘤和 SCC 等猫癌症。Imprimed</li>
<li>数据存档，Volition TAM 模型</li>
<li>面向医疗保健：兽医肿瘤学市场洞察（2025 年 10 月）</li>
</ol>
<p><strong>关于 Volition</strong></p>
<p>关于 Volition：Volition 是一家专注于推进表观遗传学科学的跨国公司。Volition 致力于通过早期检测以及疾病和治疗监测来拯救生命并改善人类和动物在重大疾病中的预后。</p>
<p>通过其子公司，Volition 正在开发和商业化简单、易用、经济的血液检测，以帮助检测和监测一系列疾病，包括一些癌症和与 NETosis 相关的疾病，如脓毒症。早期检测和监测不仅有潜力延长患者的生命，还能改善他们的生活质量。</p>
<p>Volition 的研究和开发活动集中在比利时，在美国设有创新实验室和办公室，并在伦敦设有办公室。</p>
<p>Volition 网站上的内容不被视为本文件的一部分，也不应被视为本文件的一部分。该网站地址仅作为非活动文本引用包含在本文件中。</p>
<p><strong>媒体咨询：</strong> Louise Batchelor, Volition, [email protected], +44 (0) 7557 774620</p>
<p><strong>安全港声明</strong></p>
<p>本新闻稿或相关视频或链接中的声明可能是根据《1933 年证券法》第 27A 条和《1934 年证券交易法》第 21E 条的定义的 “前瞻性声明”，涉及可能导致实际结果与前瞻性声明中预期或预测的结果存在重大差异的风险和不确定性。诸如 “预计”、“预期”、“打算”、“计划”、“目标”、“旨在”、“目标”、“相信”、“寻求”、“估计”、“优化”、“潜在”、“目标”、“建议”、“可能”、“将”、“应该”、“或许”、“会” 等类似表达识别前瞻性声明。这些前瞻性声明涉及的主题包括，Volition 对收入机会、里程碑付款和增长的预期，Volition 基于血液的诊断、预后和疾病监测测试的有效性和可用性，Volition 开发和成功商业化这些测试平台以早期检测癌症和其他疾病的能力，以及作为这些疾病的诊断、预后或疾病监测工具的能力，Volition 对未来出版物的预期，Volition 在与第三方为其产品达成许可和/或分销协议方面的成功，以及 Volition 对这些协议条款的预期。由于众多风险和不确定性，Volition 的实际结果可能与这些前瞻性声明中所指示的结果存在重大差异，包括但不限于测试有效性研究的结果。例如，如果 Volition 未能开发和商业化诊断、预后或疾病监测产品，可能无法执行其运营计划。其他风险和不确定性包括 Volition 未能获得必要的监管许可或批准以分销和营销未来产品；市场未能接受 Volition 开发管道中的产品或 Volition 可能开发的任何其他诊断、预后或疾病监测产品；Volition 未能获得足够的知识产权保护；Volition 将面临激烈的竞争，且由于诊断和疾病监测市场的高度竞争性及其快速的技术变革，Volition 计划中的产品可能会变得过时；国内和国际经济的下滑；以及其他风险，包括在 Volition 最近的 10-K 表格年度报告和 10-Q 表格季度报告中识别的风险，以及 Volition 向证券交易委员会提交的其他文件。这些声明基于当前的预期、估计和关于 Volition 业务的预测，部分基于管理层做出的假设。这些声明并不保证未来的表现，并涉及难以预测的风险、不确定性和假设。前瞻性声明是在本发布之日作出的，除法律要求外，Volition 不承担更新其前瞻性声明以反映未来事件或情况的义务。</p>
<p>rNuQ™、Nucleosomics™、Capture-PCR™、Capture-Seq™和 Nu.Q®及其各自的标志是 VolitionRx Limited 及其子公司的商标和/或服务标志。本新闻稿或相关视频或链接中提到的所有其他商标、服务标志和商号均为其各自所有者的财产。此外，除非另有说明，所有提及的 “$” 均指美国法定货币。</p>
<p>图片 - https://mma.prnewswire.com/media/2973726/VolitionRx_Limited.jpg</p>
<p>来源：VolitionRx Limited</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTA2Jk5ld3NJdGVtSWQ9TE41MjU5NyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MDYwODE3UFJfTkVXU19VU1BSX19fX19MTjUyNTk3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTA2Jk5ld3NJdGVtSWQ9TE41MjU5NyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MDYwODE3UFJfTkVXU19VU1BSX19fX19MTjUyNTk3"/></p>

VNRX

<p>VolitionRx Limited 已提交一份临床手稿以供同行评审，内容涉及其 Nu.Q® Vet Feline 原型检测，能够以 97% 的特异性准确检测猫的淋巴瘤。这一突破可能解锁 500 万美元的里程碑付款，并满足兽医学中的重要需求。该公司旨在使宠物的癌症筛查成为常规，预计猫科测试将使其市场潜力翻倍。预计到 2025 年，北美兽医肿瘤学市场将达到 17.7 亿美元，猫科治疗的意识和关注度不断提高，推动了市场增长</p>

<p><strong><em>The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment</em></strong></p>
<div class="lb-trans"><p><strong><em>本研究在同行评审期刊上的发表预计将解锁 500 万美元的合同里程碑付款</em></strong></p>
</div><p>, /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (&#34;Volition&#34;), a multi-national epigenetics company, announces submission for peer review a clinical manuscript1 reporting the high accuracy of its Nu.Q® Vet Feline prototype assay in detecting lymphoma in cats, the most common cancer in the species2. At 97% specificity the assay detected 86% of feline lymphomas1. This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in veterinary medicine.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX)（&#34;Volition&#34;），一家跨国表观遗传学公司，宣布提交一篇临床手稿进行同行评审，报告其 Nu.Q® Vet Feline 原型检测在检测猫淋巴瘤（该物种中最常见的癌症）方面的高准确性。该检测在 97% 的特异性下检测到了 86% 的猫淋巴瘤。这一突破标志着我们预计将开发出全球首个简单、经济的基于血液的猫癌症液体活检测试，这在兽医学中是一个重要的未满足需求。</p>
</div><p><strong>Dr Annalisa Canale,</strong> Volition and first author on the paper commented:</p>
<div class="lb-trans"><p><strong>安娜丽莎·卡纳莱博士，</strong> Volition 的首席作者评论道：</p>
</div><p>&#34;Feline oncology lacks tumor biomarkers and so cancer in cats have been notoriously difficult to diagnose early.</p>
<div class="lb-trans"><p>&#34;猫肿瘤学缺乏肿瘤生物标志物，因此猫的癌症早期诊断一直非常困难。</p>
</div><p>&#34;Building on our prior findings for canine lymphoma3-5, this study aimed to highlight the utility of circulating nucleosomes as biomarker to differentiate healthy vs intermediate-large cell lymphoma in cats.</p>
<div class="lb-trans"><p>&#34;基于我们之前对犬淋巴瘤的研究，本研究旨在强调循环核小体作为生物标志物的实用性，以区分健康与中大型细胞淋巴瘤的猫。</p>
</div><p>&#34;Nucleosome levels were significantly higher in cats with intermediate-large cell lymphoma compared to healthy controls indicating the potential role of H3.1-nucleosomes as a new useful biomarker for screening intermediate-large cell lymphoma in cats.&#34;</p>
<div class="lb-trans"><p>&#34;中大型细胞淋巴瘤的猫的核小体水平显著高于健康对照，表明 H3.1-核小体作为筛查猫中大型细胞淋巴瘤的新有用生物标志物的潜在作用。&#34;</p>
</div><p><strong>Gael Forterre</strong>, Chief Commercial Officer, Volition commented:</p>
<div class="lb-trans"><p><strong>盖尔·福特尔，</strong> Volition 首席商业官评论道：</p>
</div><p>&#34;This represents a tremendous commercial opportunity for Volition:</p>
<div class="lb-trans"><p>&#34;这代表了 Volition 的巨大商业机会：</p>
</div><ul>
<li>the publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment; and</li>
<li>we plan to generate ongoing revenue in this large and growing market where our technology meets an unmet need.</li>
</ul>
<div class="lb-trans"><ul>
<li>本研究在同行评审期刊上的发表预计将解锁 500 万美元的合同里程碑付款；并且</li>
<li>我们计划在这个庞大且快速增长的市场中产生持续的收入，我们的技术满足了未满足的需求。</li>
</ul>
</div><p>&#34;Our mission is to make cancer screening a routine part of every pet's annual wellness check and following the successful international rollout of our canine cancer test, we have now demonstrated that our technology is also effective for cats.</p>
<div class="lb-trans"><p>&#34;我们的使命是使癌症筛查成为每只宠物年度健康检查的常规部分，在成功国际推广我们的犬癌症检测后，我们现在已经证明我们的技术对猫也有效。</p>
</div><p>&#34;We look forward to completing product development and making the Nu.Q® Vet Feline Test available through our distribution networks including reference laboratories and point-of-care platforms.</p>
<div class="lb-trans"><p>&#34;我们期待完成产品开发，并通过我们的分销网络（包括参考实验室和即时检测平台）使 Nu.Q® Vet Feline 测试可用。</p>
</div><p>&#34;The Nu.Q® Vet Canine test is already available in more than 20 countries, and we believe the addition of a feline equivalent could potentially double our total addressable market in the companion animal space.&#34;</p>
<div class="lb-trans"><p>&#34;Nu.Q® Vet Canine 测试已经在 20 多个国家可用，我们相信增加一个猫的等效测试可能会使我们在伴侣动物领域的总可寻址市场翻倍。&#34;</p>
</div><p>The Nu.Q® Vet Feline Test taps into a significant, rapidly growing market:</p>
<div class="lb-trans"><p>Nu.Q® Vet Feline 测试切入了一个重要的、快速增长的市场：</p>
</div><ul>
<li><strong>Large Population:</strong> There are approximately <strong>73.8 million pet cats in the United States</strong> alone6.</li>
<li><strong>High Risk:</strong> It is estimated that approximately <strong>1 in 5 cats</strong> will develop cancer in their lifetime7. Feline lymphoma, the most common cancer in the species, is a primary target for the Nu.Q® assay.</li>
<li><strong>The &#34;Senior&#34; Segment:</strong> Over <strong>25% of U.S. cats</strong> are considered seniors (aged 8+) 8, representing a recurring annual screening opportunity for over 18 million pets in the U.S.6,8</li>
<li><strong>Market Growth:</strong> The North American veterinary oncology market is projected to reach <strong>$1.77 billion by 2025</strong>, with the feline segment expected to grow at a faster Compound Annual Growth Rate than the canine segment due to increasing owner awareness and a growing focus on feline-specific treatments&#34;9.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>庞大的人口：</strong> 美国仅有约 <strong>7380 万只宠物猫</strong>。</li>
<li><strong>高风险：</strong> 估计约 <strong>五分之一的猫</strong> 在其一生中会患上癌症。猫淋巴瘤是该物种中最常见的癌症，是 Nu.Q®检测的主要目标。</li>
<li><strong>“老年” 群体：</strong> 超过 <strong>25% 的美国猫</strong> 被认为是老年猫（年龄 8 岁以上），这为美国超过 1800 万只宠物提供了每年定期筛查的机会。</li>
<li><strong>市场增长：</strong> 北美兽医肿瘤学市场预计到 2025 年将达到 <strong>17.7 亿美元</strong>，其中猫的细分市场预计将以比犬类细分市场更快的复合年增长率增长，原因是主人意识的提高和对猫特定治疗的关注增加。&#34;</li>
</ul>
</div><p>The paper should be available on a preprint service in the coming days.</p>
<div class="lb-trans"><p>该论文将在接下来的几天内在预印本服务上发布。</p>
</div><ol>
<li>Data on File</li>
<li>Vail D, Thamm D, Liptak J, eds. Withrow and MacEwen's Small Animal Clinical Oncology. 6th ed. Elsevier Health Sciences; 2019.</li>
<li>H. M. Wilson‑Robles et al, BMC Vet Res, 2022, https://doi.org/10.1186/s12917-022-03429-8</li>
<li>C. Dolan et al, BMC Vet Res, 2021 https://doi.org/10.1186/s12917-021-02991-x</li>
<li>H. M. Wilson‑Robles et al, BMC Vet Res, 2021, https://doi.org/10.1186/s12917-021-02934-6</li>
<li><em>AVMA Pet Ownership Sourcebook</em> <em>(2025)</em> &amp; <em>APPA National Pet Owners Survey (2025)</em></li>
<li>Can Cats Get Cancer? Understanding Feline Cancers Like Lymphoma &amp; SCC. Imprimed</li>
<li>Data on file, Volition TAM model</li>
<li>Towards Healthcare: Veterinary Oncology Market Insights (October 2025)</li>
</ol>
<div class="lb-trans"><ol>
<li>数据存档</li>
<li>Vail D, Thamm D, Liptak J, eds. Withrow and MacEwen's Small Animal Clinical Oncology. 第 6 版. Elsevier Health Sciences; 2019。</li>
<li>H. M. Wilson‑Robles 等，BMC Vet Res, 2022, https://doi.org/10.1186/s12917-022-03429-8</li>
<li>C. Dolan 等，BMC Vet Res, 2021 https://doi.org/10.1186/s12917-021-02991-x</li>
<li>H. M. Wilson‑Robles 等，BMC Vet Res, 2021, https://doi.org/10.1186/s12917-021-02934-6</li>
<li><em>AVMA 宠物拥有源书</em> <em>(2025)</em> 6 <em>APPA 全国宠物主人调查 (2025)</em></li>
<li>猫会得癌症吗？了解猫淋巴瘤和 SCC 等猫癌症。Imprimed</li>
<li>数据存档，Volition TAM 模型</li>
<li>面向医疗保健：兽医肿瘤学市场洞察（2025 年 10 月）</li>
</ol>
</div><p><strong>About Volition</strong></p>
<div class="lb-trans"><p><strong>关于 Volition</strong></p>
</div><p>About Volition: Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.</p>
<div class="lb-trans"><p>关于 Volition：Volition 是一家专注于推进表观遗传学科学的跨国公司。Volition 致力于通过早期检测以及疾病和治疗监测来拯救生命并改善人类和动物在重大疾病中的预后。</p>
</div><p>Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.</p>
<div class="lb-trans"><p>通过其子公司，Volition 正在开发和商业化简单、易用、经济的血液检测，以帮助检测和监测一系列疾病，包括一些癌症和与 NETosis 相关的疾病，如脓毒症。早期检测和监测不仅有潜力延长患者的生命，还能改善他们的生活质量。</p>
</div><p>Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.</p>
<div class="lb-trans"><p>Volition 的研究和开发活动集中在比利时，在美国设有创新实验室和办公室，并在伦敦设有办公室。</p>
</div><p>The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.</p>
<div class="lb-trans"><p>Volition 网站上的内容不被视为本文件的一部分，也不应被视为本文件的一部分。该网站地址仅作为非活动文本引用包含在本文件中。</p>
</div><p><strong>Media Enquiries:</strong> Louise Batchelor, Volition, [email protected], +44 (0) 7557 774620</p>
<div class="lb-trans"><p><strong>媒体咨询：</strong> Louise Batchelor, Volition, [email protected], +44 (0) 7557 774620</p>
</div><p><strong>Safe Harbor Statement</strong></p>
<div class="lb-trans"><p><strong>安全港声明</strong></p>
</div><p>Statements in this press release or associated video or link may be &#34;forward-looking statements&#34; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as &#34;expects,&#34; &#34;anticipates,&#34; &#34;intends,&#34; &#34;plans,&#34; &#34;aims,&#34; &#34;targets,&#34; &#34;believes,&#34; &#34;seeks,&#34; &#34;estimates,&#34; &#34;optimizing,&#34; &#34;potential,&#34; &#34;goal,&#34; &#34;suggests,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;may,&#34; &#34;will&#34; and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities, milestone payments and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.</p>
<div class="lb-trans"><p>本新闻稿或相关视频或链接中的声明可能是根据《1933 年证券法》第 27A 条和《1934 年证券交易法》第 21E 条的定义的 “前瞻性声明”，涉及可能导致实际结果与前瞻性声明中预期或预测的结果存在重大差异的风险和不确定性。诸如 “预计”、“预期”、“打算”、“计划”、“目标”、“旨在”、“目标”、“相信”、“寻求”、“估计”、“优化”、“潜在”、“目标”、“建议”、“可能”、“将”、“应该”、“或许”、“会” 等类似表达识别前瞻性声明。这些前瞻性声明涉及的主题包括，Volition 对收入机会、里程碑付款和增长的预期，Volition 基于血液的诊断、预后和疾病监测测试的有效性和可用性，Volition 开发和成功商业化这些测试平台以早期检测癌症和其他疾病的能力，以及作为这些疾病的诊断、预后或疾病监测工具的能力，Volition 对未来出版物的预期，Volition 在与第三方为其产品达成许可和/或分销协议方面的成功，以及 Volition 对这些协议条款的预期。由于众多风险和不确定性，Volition 的实际结果可能与这些前瞻性声明中所指示的结果存在重大差异，包括但不限于测试有效性研究的结果。例如，如果 Volition 未能开发和商业化诊断、预后或疾病监测产品，可能无法执行其运营计划。其他风险和不确定性包括 Volition 未能获得必要的监管许可或批准以分销和营销未来产品；市场未能接受 Volition 开发管道中的产品或 Volition 可能开发的任何其他诊断、预后或疾病监测产品；Volition 未能获得足够的知识产权保护；Volition 将面临激烈的竞争，且由于诊断和疾病监测市场的高度竞争性及其快速的技术变革，Volition 计划中的产品可能会变得过时；国内和国际经济的下滑；以及其他风险，包括在 Volition 最近的 10-K 表格年度报告和 10-Q 表格季度报告中识别的风险，以及 Volition 向证券交易委员会提交的其他文件。这些声明基于当前的预期、估计和关于 Volition 业务的预测，部分基于管理层做出的假设。这些声明并不保证未来的表现，并涉及难以预测的风险、不确定性和假设。前瞻性声明是在本发布之日作出的，除法律要求外，Volition 不承担更新其前瞻性声明以反映未来事件或情况的义务。</p>
</div><p>rNuQ™, Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to &#34;$&#34; refer to the legal currency of the United States of America.</p>
<div class="lb-trans"><p>rNuQ™、Nucleosomics™、Capture-PCR™、Capture-Seq™和 Nu.Q®及其各自的标志是 VolitionRx Limited 及其子公司的商标和/或服务标志。本新闻稿或相关视频或链接中提到的所有其他商标、服务标志和商号均为其各自所有者的财产。此外，除非另有说明，所有提及的 “$” 均指美国法定货币。</p>
</div><p>Image - https://mma.prnewswire.com/media/2973726/VolitionRx_Limited.jpg</p>
<div class="lb-trans"><p>图片 - https://mma.prnewswire.com/media/2973726/VolitionRx_Limited.jpg</p>
</div><p>SOURCE VolitionRx Limited</p>
<div class="lb-trans"><p>来源：VolitionRx Limited</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTA2Jk5ld3NJdGVtSWQ9TE41MjU5NyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MDYwODE3UFJfTkVXU19VU1BSX19fX19MTjUyNTk3" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LN52597&amp;Transmission_Id=202605060817PR_NEWS_USPR_____LN52597&amp;DateId=20260506"/></p>

08:17 ET VolitionRx 宣布提交关于 Nu.Q®兽医癌症测试在猫中应用的手稿